Mi Ra Yu
Impact in
- Nephrology top 1%
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Clinical Biochemistry top 1%
- Advanced Glycation End Products research
Papers in
- Nephrology 11
- Chronic Kidney Disease and Diabetes 7
- Dialysis and Renal Disease Management 4
-
- Advanced Glycation End Products research 4
- Co-authors
- Hunjoo HaHyunjin NohHi Bahl LeeJi Yeon SeoYoon Jin ChoiMasanori KitamuraJae Sook SongDong Cheol Han
- Journals
- Kidney International (7 papers)Cancer Research (5 papers)Aging Cell (2 papers)Peritoneal Dialysis International (2 papers)The Journal of Immunology (2 papers)
- Partner nations
- South KoreaChinaLebanon
In The Last Decade
Mi Ra Yu
40 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 104
- Nephrology 586
- Clinical Biochemistry 322
- Molecular Biology 887
- Cancer Research 193
- Aging 22
Countries citing papers authored by Mi Ra Yu
This map shows the geographic impact of Mi Ra Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mi Ra Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mi Ra Yu more than expected).
Fields of papers citing papers by Mi Ra Yu
This network shows the impact of papers produced by Mi Ra Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mi Ra Yu. The network helps show where Mi Ra Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Mi Ra Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 15 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 0 | |
| 4 | 2022 | 35 | |
| 5 | 2022 | 8 | |
| 6 | 2022 | 7 | |
| 7 | 2021 | 36 | |
| 8 | 2016 | 42 | |
| 9 | 2016 | 12 | |
| 10 | 2016 | 6 | |
| 11 | 2012 | 66 | |
| 12 | 2011 | 68 | |
| 13 | 2009 | 225 | |
| 14 | 2007 | 46 | |
| 15 | 2007 | 20 | |
| 16 | 2002 | 242 | |
| 17 | 2001 | 52 | |
| 18 | 2001 | 47 | |
| 19 | 2001 | 138 | |
| 20 | 1998 | 120 |
About Mi Ra Yu
Mi Ra Yu is a scholar working on Nephrology, Clinical Biochemistry, Cancer Research, Oncology and Molecular Biology, having authored 41 papers that have together received 2.1k indexed citations. Recurring topics across this work include Chronic Kidney Disease and Diabetes (7 papers), Lung Cancer Treatments and Mutations (6 papers), Dialysis and Renal Disease Management (4 papers), Epigenetics and DNA Methylation (4 papers), Advanced Glycation End Products research (4 papers), MicroRNA in disease regulation (3 papers), HER2/EGFR in Cancer Research (3 papers) and Cancer-related molecular mechanisms research (3 papers). The work is most often cited by research in Nephrology (586 citations), Clinical Biochemistry (322 citations), Molecular Biology (887 citations), Cancer Research (193 citations) and Aging (22 citations). Mi Ra Yu has collaborated with scholars based in South Korea, China and Lebanon. Frequent co-authors include Hunjoo Ha, Hyunjin Noh, Hi Bahl Lee, Ji Yeon Seo, Yoon Jin Choi, Masanori Kitamura, Jae Sook Song, Dong Cheol Han, Jin Seok Jeon and Young Ok Kim. Their work appears in journals such as Kidney International, Cancer Research, Aging Cell, Peritoneal Dialysis International and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.